WO2003026743A3 - Opioid formulations having reduced potential for abuse - Google Patents
Opioid formulations having reduced potential for abuse Download PDFInfo
- Publication number
- WO2003026743A3 WO2003026743A3 PCT/US2002/030393 US0230393W WO03026743A3 WO 2003026743 A3 WO2003026743 A3 WO 2003026743A3 US 0230393 W US0230393 W US 0230393W WO 03026743 A3 WO03026743 A3 WO 03026743A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- abuse
- reduced potential
- opioid formulations
- opioid
- formulations
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/485—Morphinan derivatives, e.g. morphine, codeine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2009—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
- A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
Abstract
Priority Applications (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CA002459976A CA2459976A1 (en) | 2001-09-26 | 2002-09-25 | Opioid formulations having reduced potential for abuse |
JP2003530373A JP2005523876A (en) | 2001-09-26 | 2002-09-25 | Opioid formulations with reduced potential for abuse |
EP02773571A EP1429730A4 (en) | 2001-09-26 | 2002-09-25 | Opioid formulations having reduced potential for abuse |
AU2002337686A AU2002337686B2 (en) | 2001-09-26 | 2002-09-25 | Opioid formulations having reduced potential for abuse |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US32454601P | 2001-09-26 | 2001-09-26 | |
US60/324,546 | 2001-09-26 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2003026743A2 WO2003026743A2 (en) | 2003-04-03 |
WO2003026743A3 true WO2003026743A3 (en) | 2003-10-16 |
Family
ID=23264062
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2002/030393 WO2003026743A2 (en) | 2001-09-26 | 2002-09-25 | Opioid formulations having reduced potential for abuse |
Country Status (6)
Country | Link |
---|---|
US (2) | US20030091635A1 (en) |
EP (1) | EP1429730A4 (en) |
JP (2) | JP2005523876A (en) |
AU (1) | AU2002337686B2 (en) |
CA (1) | CA2459976A1 (en) |
WO (1) | WO2003026743A2 (en) |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8901113B2 (en) | 2009-09-30 | 2014-12-02 | Acura Pharmaceuticals, Inc. | Methods and compositions for deterring abuse |
US9101636B2 (en) | 2012-11-30 | 2015-08-11 | Acura Pharmaceuticals, Inc. | Methods and compositions for self-regulated release of active pharmaceutical ingredient |
US9492443B2 (en) | 2003-11-26 | 2016-11-15 | Acura Pharmaceuticals, Inc. | Abuse deterrent compositions and methods of making same |
US9572779B2 (en) | 2010-12-22 | 2017-02-21 | Purdue Pharma L.P. | Encased tamper resistant controlled release dosage forms |
Families Citing this family (94)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5478577A (en) * | 1993-11-23 | 1995-12-26 | Euroceltique, S.A. | Method of treating pain by administering 24 hour oral opioid formulations exhibiting rapid rate of initial rise of plasma drug level |
US8329216B2 (en) * | 2001-07-06 | 2012-12-11 | Endo Pharmaceuticals Inc. | Oxymorphone controlled release formulations |
WO2003004032A1 (en) * | 2001-07-06 | 2003-01-16 | Endo Pharmaceuticals, Inc. | Oral administration of 6-hydroxy-oxymorphone for use as an analgesic |
PL207748B1 (en) * | 2001-07-06 | 2011-01-31 | Penwest Pharmaceuticals Company | Sustained release formulations of oxymorphone |
US20030068375A1 (en) | 2001-08-06 | 2003-04-10 | Curtis Wright | Pharmaceutical formulation containing gelling agent |
JP2005523876A (en) * | 2001-09-26 | 2005-08-11 | ペンウェスト ファーマシューティカルズ カンパニー | Opioid formulations with reduced potential for abuse |
US20050182056A9 (en) * | 2002-02-21 | 2005-08-18 | Seth Pawan | Modified release formulations of at least one form of tramadol |
US8128957B1 (en) | 2002-02-21 | 2012-03-06 | Valeant International (Barbados) Srl | Modified release compositions of at least one form of tramadol |
US7776314B2 (en) | 2002-06-17 | 2010-08-17 | Grunenthal Gmbh | Abuse-proofed dosage system |
US20040109886A1 (en) * | 2002-08-27 | 2004-06-10 | Larry Rigby | Methods and apparatus for transdermal delivery of abusable drugs with a deterrent agent |
ES2677769T3 (en) | 2002-09-20 | 2018-08-06 | Alpharma Pharmaceuticals Llc | Sequestering subunit and related compositions and procedures |
WO2004026262A2 (en) * | 2002-09-23 | 2004-04-01 | Verion, Inc. | Abuse-resistant pharmaceutical compositions |
US8906413B2 (en) * | 2003-05-12 | 2014-12-09 | Supernus Pharmaceuticals, Inc. | Drug formulations having reduced abuse potential |
DE102005005446A1 (en) | 2005-02-04 | 2006-08-10 | Grünenthal GmbH | Break-resistant dosage forms with sustained release |
US8075872B2 (en) | 2003-08-06 | 2011-12-13 | Gruenenthal Gmbh | Abuse-proofed dosage form |
DE10361596A1 (en) | 2003-12-24 | 2005-09-29 | Grünenthal GmbH | Process for producing an anti-abuse dosage form |
DE10336400A1 (en) | 2003-08-06 | 2005-03-24 | Grünenthal GmbH | Anti-abuse dosage form |
US20070048228A1 (en) | 2003-08-06 | 2007-03-01 | Elisabeth Arkenau-Maric | Abuse-proofed dosage form |
DE102004032051A1 (en) | 2004-07-01 | 2006-01-19 | Grünenthal GmbH | Process for the preparation of a secured against misuse, solid dosage form |
EP1740156B8 (en) * | 2004-04-22 | 2012-07-11 | Grünenthal GmbH | Method for the production of an abuse-proof, solid form of administration |
EP3326617A1 (en) | 2004-06-12 | 2018-05-30 | Collegium Pharmaceutical, Inc. | Abuse-deterrent drug formulations |
DE102004032049A1 (en) | 2004-07-01 | 2006-01-19 | Grünenthal GmbH | Anti-abuse, oral dosage form |
US7226619B1 (en) | 2004-09-07 | 2007-06-05 | Pharmorx Inc. | Material for controlling diversion of medications |
EP1809259B1 (en) * | 2004-10-15 | 2014-12-03 | Supernus Pharmaceuticals, Inc. | Less abusable pharmaceutical preparations |
US7827983B2 (en) * | 2004-12-20 | 2010-11-09 | Hewlett-Packard Development Company, L.P. | Method for making a pharmaceutically active ingredient abuse-prevention device |
DE102005005449A1 (en) | 2005-02-04 | 2006-08-10 | Grünenthal GmbH | Process for producing an anti-abuse dosage form |
WO2006133733A1 (en) | 2005-06-13 | 2006-12-21 | Flamel Technologies | Oral dosage form comprising an antimisuse system |
US20070162369A1 (en) * | 2006-01-09 | 2007-07-12 | Hardison Joseph H Iii | Internet-based method of and system for transfering and exercising monetary rights within a financial marketplace |
US8626626B2 (en) | 2006-01-09 | 2014-01-07 | Interest Capturing Systems, Llc | Method of and system for capturing interest earned on the monetary value of transferred monetary rights managed on an internet-based monetary rights transfer (MRT) network supported by a real-time gross settlement (RTGS) system |
US20070212414A1 (en) * | 2006-03-08 | 2007-09-13 | Penwest Pharmaceuticals Co. | Ethanol-resistant sustained release formulations |
GB0606124D0 (en) * | 2006-03-28 | 2006-05-03 | Reckitt Benckiser Healthcare | Buprenorphine derivatives and uses thereof |
SI2484346T1 (en) | 2006-06-19 | 2017-05-31 | Alpharma Pharmaceuticals Llc | Pharmaceutical compositions |
EP2097069A1 (en) * | 2006-10-10 | 2009-09-09 | Penwest Pharmaceuticals Co. | Robust sustained release formulations of oxymorphone |
CN101578094A (en) * | 2006-10-10 | 2009-11-11 | 潘威斯脱药物公司 | Robust sustained release formulations of oxymorphone and methods of use thereof |
MX2009003771A (en) * | 2006-10-10 | 2009-07-22 | Penwest Pharmaceuticals Co | Robust sustained release formulations. |
JP2010506833A (en) * | 2006-10-11 | 2010-03-04 | アルファーマ,インコーポレイテッド | Pharmaceutical composition |
US20080293695A1 (en) * | 2007-05-22 | 2008-11-27 | David William Bristol | Salts of physiologically active and psychoactive alkaloids and amines simultaneously exhibiting bioavailability and abuse resistance |
DE102007011485A1 (en) | 2007-03-07 | 2008-09-11 | Grünenthal GmbH | Dosage form with more difficult abuse |
US8846766B2 (en) * | 2007-05-22 | 2014-09-30 | Pisgah Laboratories, Inc. | Abuse-deterrent methadone for the safe treatment of drug abuse and pain relief |
EP2155167A2 (en) | 2007-06-04 | 2010-02-24 | Egalet A/S | Controlled release pharmaceutical compositions for prolonged effect |
US20090124650A1 (en) * | 2007-06-21 | 2009-05-14 | Endo Pharmaceuticals, Inc. | Method of Treating Pain Utilizing Controlled Release Oxymorphone Pharmaceutical Compositions and Instructions on Effects of Alcohol |
US20080318994A1 (en) | 2007-06-21 | 2008-12-25 | Endo Pharmaceuticals, Inc. | Method of Treating Pain Utilizing Controlled Release Oxymorphone Pharmaceutical Compositions and Instruction on Dosing for Renal Impairment |
US20080318993A1 (en) * | 2007-06-21 | 2008-12-25 | Endo Pharmaceuticals, Inc. | Method of Treating Pain Utilizing Controlled Release Oxymorphone Pharmaceutical Compositions and Instruction on Dosing for Hepatic Impairment |
WO2009036811A1 (en) * | 2007-09-21 | 2009-03-26 | Evonik Röhm Gmbh | Ph-dependent controlled release pharmaceutical composition for non-opioids with resistance against the influence of ethanol |
JP5651818B2 (en) | 2007-12-17 | 2015-01-14 | パラディン ラブス インコーポレーテッド | Controlled release formulation to prevent misuse |
US8623418B2 (en) | 2007-12-17 | 2014-01-07 | Alpharma Pharmaceuticals Llc | Pharmaceutical composition |
CA2709905A1 (en) * | 2007-12-17 | 2009-06-25 | Alfred Liang | Abuse-resistant oxycodone composition |
RU2493830C2 (en) | 2008-01-25 | 2013-09-27 | Грюненталь Гмбх | Drug form |
US8372432B2 (en) | 2008-03-11 | 2013-02-12 | Depomed, Inc. | Gastric retentive extended-release dosage forms comprising combinations of a non-opioid analgesic and an opioid analgesic |
CA2720108C (en) * | 2008-03-11 | 2016-06-07 | Depomed, Inc. | Gastric retentive extended-release dosage forms comprising combinations of a non-opioid analgesic and an opioid analgesic |
BRPI0912014A2 (en) | 2008-05-09 | 2019-03-06 | Grünenthal GmbH | A process for preparing an intermediate powder formulation and a final solid dosage form using a spray freeze step |
EP2379111B1 (en) * | 2008-12-12 | 2013-03-20 | Paladin Labs Inc. | Narcotic drug formulations with decreased abuse potential |
WO2010069050A1 (en) | 2008-12-16 | 2010-06-24 | Labopharm Inc. | Misuse preventative, controlled release formulation |
WO2010089132A1 (en) | 2009-02-06 | 2010-08-12 | Egalet A/S | Immediate release composition resistant to abuse by intake of alcohol |
US8255296B2 (en) | 2009-06-11 | 2012-08-28 | Interest Capturing Systems, Llc | System for implementing a security issuer rights management process over a distributed communications network, deployed in a financial marketplace |
WO2010149169A2 (en) | 2009-06-24 | 2010-12-29 | Egalet A/S | Controlled release formulations |
JP2012533585A (en) | 2009-07-22 | 2012-12-27 | グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング | Tamper-resistant dosage forms for oxidation-sensitive opioids |
BR112012001547A2 (en) | 2009-07-22 | 2016-03-08 | Gruenenthal Gmbh | hot melt extruded pharmaceutical dosage form |
US20110052685A1 (en) * | 2009-08-31 | 2011-03-03 | Depomed, Inc. | Gastric retentive pharmaceutical compositions for immediate and extended release of acetaminophen |
US10668060B2 (en) | 2009-12-10 | 2020-06-02 | Collegium Pharmaceutical, Inc. | Tamper-resistant pharmaceutical compositions of opioids and other drugs |
US9198861B2 (en) | 2009-12-22 | 2015-12-01 | Mallinckrodt Llc | Methods of producing stabilized solid dosage pharmaceutical compositions containing morphinans |
US8597681B2 (en) | 2009-12-22 | 2013-12-03 | Mallinckrodt Llc | Methods of producing stabilized solid dosage pharmaceutical compositions containing morphinans |
FR2960775A1 (en) * | 2010-06-07 | 2011-12-09 | Ethypharm Sa | MICROGRANULES RESISTANT TO MISMATCH |
WO2012028319A1 (en) | 2010-09-02 | 2012-03-08 | Grünenthal GmbH | Tamper resistant dosage form comprising inorganic salt |
WO2012028318A1 (en) | 2010-09-02 | 2012-03-08 | Grünenthal GmbH | Tamper resistant dosage form comprising an anionic polymer |
US9233073B2 (en) | 2010-12-23 | 2016-01-12 | Purdue Pharma L.P. | Tamper resistant solid oral dosage forms |
AU2012219322A1 (en) * | 2011-02-17 | 2013-05-09 | QRxPharma Ltd. | Technology for preventing abuse of solid dosage forms |
US9050335B1 (en) | 2011-05-17 | 2015-06-09 | Mallinckrodt Llc | Pharmaceutical compositions for extended release of oxycodone and acetaminophen resulting in a quick onset and prolonged period of analgesia |
US8858963B1 (en) | 2011-05-17 | 2014-10-14 | Mallinckrodt Llc | Tamper resistant composition comprising hydrocodone and acetaminophen for rapid onset and extended duration of analgesia |
US8741885B1 (en) | 2011-05-17 | 2014-06-03 | Mallinckrodt Llc | Gastric retentive extended release pharmaceutical compositions |
BR112014002022A2 (en) | 2011-07-29 | 2017-02-21 | Gruenenthal Gmbh | tamper-resistant tablet providing immediate drug release |
CN103857386A (en) | 2011-07-29 | 2014-06-11 | 格吕伦塔尔有限公司 | Tamper-resistant tablet providing immediate drug release |
US20130225697A1 (en) | 2012-02-28 | 2013-08-29 | Grunenthal Gmbh | Tamper-resistant dosage form comprising pharmacologically active compound and anionic polymer |
AU2013248351B2 (en) | 2012-04-18 | 2018-04-26 | Grunenthal Gmbh | Tamper resistant and dose-dumping resistant pharmaceutical dosage form |
US10064945B2 (en) | 2012-05-11 | 2018-09-04 | Gruenenthal Gmbh | Thermoformed, tamper-resistant pharmaceutical dosage form containing zinc |
WO2014011830A1 (en) | 2012-07-12 | 2014-01-16 | Mallinckrodt Llc | Extended release, abuse deterrent pharmaceutical compositions |
US20140161879A1 (en) * | 2012-07-31 | 2014-06-12 | Zogenix, Inc. | Treating pain in patients with hepatic impairment |
EA201500742A1 (en) | 2013-02-05 | 2015-12-30 | Пердью Фарма Л.П. | PHARMACEUTICAL COMPOSITIONS PROTECTED FROM NON-GOAL USE |
US10751287B2 (en) | 2013-03-15 | 2020-08-25 | Purdue Pharma L.P. | Tamper resistant pharmaceutical formulations |
MX2015016254A (en) | 2013-05-29 | 2016-04-20 | Gruenenthal Gmbh | Tamper resistant dosage form with bimodal release profile. |
BR112015026549A2 (en) | 2013-05-29 | 2017-07-25 | Gruenenthal Gmbh | tamper-proof dosage form containing one or more particles |
AU2014289187B2 (en) | 2013-07-12 | 2019-07-11 | Grunenthal Gmbh | Tamper-resistant dosage form containing ethylene-vinyl acetate polymer |
JP6539274B2 (en) | 2013-08-12 | 2019-07-03 | ファーマシューティカル マニュファクチュアリング リサーチ サービシズ,インコーポレーテッド | Extruded immediate release abuse deterrent pills |
CA2931553C (en) | 2013-11-26 | 2022-01-18 | Grunenthal Gmbh | Preparation of a powdery pharmaceutical composition by means of cryo-milling |
US10172797B2 (en) | 2013-12-17 | 2019-01-08 | Pharmaceutical Manufacturing Research Services, Inc. | Extruded extended release abuse deterrent pill |
US9492444B2 (en) | 2013-12-17 | 2016-11-15 | Pharmaceutical Manufacturing Research Services, Inc. | Extruded extended release abuse deterrent pill |
MX2016014738A (en) | 2014-05-12 | 2017-03-06 | Gruenenthal Gmbh | Tamper resistant immediate release capsule formulation comprising tapentadol. |
WO2015181059A1 (en) | 2014-05-26 | 2015-12-03 | Grünenthal GmbH | Multiparticles safeguarded against ethanolic dose-dumping |
ES2809458T3 (en) | 2014-07-17 | 2021-03-04 | Pharmaceutical Manufacturing Res Services Inc | Liquid filled, abuse deterrent and immediate release dosage form |
AU2015336065A1 (en) | 2014-10-20 | 2017-05-04 | Pharmaceutical Manufacturing Research Services, Inc. | Extended release abuse deterrent liquid fill dosage form |
AU2016251854A1 (en) | 2015-04-24 | 2017-10-19 | Grunenthal Gmbh | Tamper-resistant dosage form with immediate release and resistance against solvent extraction |
US11103581B2 (en) | 2015-08-31 | 2021-08-31 | Acura Pharmaceuticals, Inc. | Methods and compositions for self-regulated release of active pharmaceutical ingredient |
JP2018526414A (en) | 2015-09-10 | 2018-09-13 | グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング | Protection against oral overdose with abuse-inhibiting immediate release formulations |
WO2017222575A1 (en) | 2016-06-23 | 2017-12-28 | Collegium Pharmaceutical, Inc. | Process of making more stable abuse-deterrent oral formulations |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6245357B1 (en) * | 1998-03-06 | 2001-06-12 | Alza Corporation | Extended release dosage form |
Family Cites Families (100)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IL26896A (en) * | 1966-01-19 | 1970-11-30 | Endo Lab | 14-hydroxynormorphines and 14-hydroxynormorphinones |
US3879555A (en) * | 1970-11-16 | 1975-04-22 | Bristol Myers Co | Method of treating drug addicts |
US3980766A (en) * | 1973-08-13 | 1976-09-14 | West Laboratories, Inc. | Orally administered drug composition for therapy in the treatment of narcotic drug addiction |
US3966940A (en) * | 1973-11-09 | 1976-06-29 | Bristol-Myers Company | Analgetic compositions |
DE2530563C2 (en) * | 1975-07-09 | 1986-07-24 | Bayer Ag, 5090 Leverkusen | Analgesic drugs with reduced potential for abuse |
US4457933A (en) * | 1980-01-24 | 1984-07-03 | Bristol-Myers Company | Prevention of analgesic abuse |
US4587249A (en) * | 1982-07-22 | 1986-05-06 | Analgesic Associates | Analgesic and anti-inflammatory compositions comprising caffeine and methods of using same |
US4656177A (en) * | 1982-07-22 | 1987-04-07 | Analgesic Associates | Analgesic and anti-inflammatory compositions comprising caffeine and methods of using same |
US4464376A (en) * | 1982-07-22 | 1984-08-07 | Richardson-Vicks, Inc. | Analgesic and anti-inflammatory compositions comprising caffeine and methods of using same |
US4567183A (en) * | 1983-03-11 | 1986-01-28 | Analgesic Associates | Analgesic and anti-inflammatory compositions comprising xanthines and methods of using same |
GB8332556D0 (en) * | 1983-12-06 | 1984-01-11 | Reckitt & Colmann Prod Ltd | Analgesic compositions |
GB8430346D0 (en) * | 1984-11-30 | 1985-01-09 | Reckitt & Colmann Prod Ltd | Analgesic compositions |
US4567186A (en) * | 1985-01-14 | 1986-01-28 | Sterling Drug Inc. | 5-Heteryl-1,6-naphthyridin-2(1H)-ones, cardiotonic use thereof and intermediates therefor |
US4569937A (en) * | 1985-02-11 | 1986-02-11 | E. I. Du Pont De Nemours And Company | Analgesic mixture of oxycodone and ibuprofen |
GB8521350D0 (en) * | 1985-08-28 | 1985-10-02 | Euro Celtique Sa | Analgesic composition |
GB8601204D0 (en) * | 1986-01-18 | 1986-02-19 | Boots Co Plc | Therapeutic agents |
US4861598A (en) * | 1986-07-18 | 1989-08-29 | Euroceltique, S.A. | Controlled release bases for pharmaceuticals |
GB8626098D0 (en) * | 1986-10-31 | 1986-12-03 | Euro Celtique Sa | Controlled release hydromorphone composition |
US4994276A (en) * | 1988-09-19 | 1991-02-19 | Edward Mendell Co., Inc. | Directly compressible sustained release excipient |
GB8728294D0 (en) * | 1987-12-03 | 1988-01-06 | Reckitt & Colmann Prod Ltd | Treatment compositions |
US5135757A (en) * | 1988-09-19 | 1992-08-04 | Edward Mendell Co., Inc. | Compressible sustained release solid dosage forms |
US5128143A (en) * | 1988-09-19 | 1992-07-07 | Edward Mendell Co., Inc. | Sustained release excipient and tablet formulation |
US5236714A (en) * | 1988-11-01 | 1993-08-17 | Alza Corporation | Abusable substance dosage form having reduced abuse potential |
US5202128A (en) * | 1989-01-06 | 1993-04-13 | F. H. Faulding & Co. Limited | Sustained release pharmaceutical composition |
US5431922A (en) * | 1991-03-05 | 1995-07-11 | Bristol-Myers Squibb Company | Method for administration of buspirone |
US5266331A (en) * | 1991-11-27 | 1993-11-30 | Euroceltique, S.A. | Controlled release oxycodone compositions |
US5580578A (en) * | 1992-01-27 | 1996-12-03 | Euro-Celtique, S.A. | Controlled release formulations coated with aqueous dispersions of acrylic polymers |
US5968551A (en) * | 1991-12-24 | 1999-10-19 | Purdue Pharma L.P. | Orally administrable opioid formulations having extended duration of effect |
GB9202464D0 (en) * | 1992-02-05 | 1992-03-18 | Danbiosyst Uk | Composition for nasal administration |
US5512578A (en) * | 1992-09-21 | 1996-04-30 | Albert Einstein College Of Medicine Of Yeshiva University, A Division Of Yeshiva University | Method of simultaneously enhancing analgesic potency and attenuating dependence liability caused by exogenous and endogenous opiod agonists |
USRE36547E (en) * | 1992-09-21 | 2000-02-01 | Albert Einstein College Of Medicine Of Yeshiva University | Method of simultaneously enhancing analgesic potency and attenuating dependence liability caused by exogenous and endogenous opioid agonists |
US5330761A (en) * | 1993-01-29 | 1994-07-19 | Edward Mendell Co. Inc. | Bioadhesive tablet for non-systemic use products |
IL110014A (en) * | 1993-07-01 | 1999-11-30 | Euro Celtique Sa | Solid controlled-release oral dosage forms of opioid analgesics |
US5455046A (en) * | 1993-09-09 | 1995-10-03 | Edward Mendell Co., Inc. | Sustained release heterodisperse hydrogel systems for insoluble drugs |
US5662933A (en) * | 1993-09-09 | 1997-09-02 | Edward Mendell Co., Inc. | Controlled release formulation (albuterol) |
US5399358A (en) * | 1993-11-12 | 1995-03-21 | Edward Mendell Co., Inc. | Sustained release formulations for 24 hour release of metroprolol |
US5543434A (en) * | 1994-02-25 | 1996-08-06 | Weg; Stuart L. | Nasal administration of ketamine to manage pain |
US5399359A (en) * | 1994-03-04 | 1995-03-21 | Edward Mendell Co., Inc. | Controlled release oxybutynin formulations |
CN1131023C (en) * | 1994-04-25 | 2003-12-17 | 潘威斯脱药物公司 | Sustained release excipient |
US5399362A (en) * | 1994-04-25 | 1995-03-21 | Edward Mendell Co., Inc. | Once-a-day metoprolol oral dosage form |
US5633000A (en) * | 1994-06-23 | 1997-05-27 | Axxia Technologies | Subcutaneous implant |
US5914131A (en) * | 1994-07-07 | 1999-06-22 | Alza Corporation | Hydromorphone therapy |
US5965161A (en) * | 1994-11-04 | 1999-10-12 | Euro-Celtique, S.A. | Extruded multi-particulates |
FR2729857B1 (en) * | 1995-01-27 | 1997-04-04 | Rhone Poulenc Chimie | PHARMACEUTICAL COMPOSITIONS IN THE FORM OF SUSTAINED-RELEASE TABLETS BASED ON GRANULES OF HIGH MOLECULAR POLYSACCHARIDES |
US5612053A (en) * | 1995-04-07 | 1997-03-18 | Edward Mendell Co., Inc. | Controlled release insufflation carrier for medicaments |
AU2068797A (en) * | 1996-01-29 | 1997-08-20 | Edward Mendell Co. Inc. | Sustained release excipient |
JP3134187B2 (en) * | 1996-03-07 | 2001-02-13 | 武田薬品工業株式会社 | Controlled release composition |
US6245351B1 (en) * | 1996-03-07 | 2001-06-12 | Takeda Chemical Industries, Ltd. | Controlled-release composition |
US6103258A (en) * | 1996-04-12 | 2000-08-15 | Simon; David Lew | Salts and bases of the 17-(Cyclopropylmethyl)-4,5 alpha-epoxy-6-Methylenemorphinan-3,14 diol molecule for optimizing dopamine homeostasis during administration of opioid analgesics |
WO1998001117A1 (en) * | 1996-07-08 | 1998-01-15 | Edward Mendell Co., Inc. | Sustained release matrix for high-dose insoluble drugs |
US6248789B1 (en) * | 1996-08-29 | 2001-06-19 | Stuart L. Weg | Administration of ketamine to manage pain and to reduce drug dependency |
US5891474A (en) * | 1997-01-29 | 1999-04-06 | Poli Industria Chimica, S.P.A. | Time-specific controlled release dosage formulations and method of preparing same |
EP0998271B3 (en) * | 1997-06-06 | 2014-10-29 | Depomed, Inc. | Gastric-retentive oral drug dosage forms for controlled release of highly soluble drugs |
US6391336B1 (en) * | 1997-09-22 | 2002-05-21 | Royer Biomedical, Inc. | Inorganic-polymer complexes for the controlled release of compounds including medicinals |
US6056977A (en) * | 1997-10-15 | 2000-05-02 | Edward Mendell Co., Inc. | Once-a-day controlled release sulfonylurea formulation |
US6193991B1 (en) * | 1997-10-29 | 2001-02-27 | Atul J. Shukla | Biodegradable delivery systems of biologically active substances |
US6375957B1 (en) * | 1997-12-22 | 2002-04-23 | Euro-Celtique, S.A. | Opioid agonist/opioid antagonist/acetaminophen combinations |
AU773642C (en) * | 1997-12-22 | 2006-04-06 | Mundipharma Pty Limited | Opioid agonist/antagonist combinations |
CN1204890C (en) * | 1997-12-22 | 2005-06-08 | 欧罗赛铁克股份有限公司 | Method for preventing abuse of opioid dosage forms |
ES2224642T3 (en) * | 1998-04-22 | 2005-03-01 | Glycologic Limited | ADMINISTRABLE COMPOSITIONS BY ORAL ROUTE, WHICH INCLUDE A POLYACARIDE RETICULATED BY A CARTON AND A DIGERABLE POLYMER IN THE LOWER GASTROINTESTINAL TRACT. |
KR20000011247A (en) * | 1998-07-23 | 2000-02-25 | 김윤 | Composition and pharmaceutical dosage form for colonic drug delivery using polysaccharides |
GB9816723D0 (en) * | 1998-08-01 | 1998-09-30 | Boots Co Plc | Therapeutic agents |
EP2020229A1 (en) * | 1998-11-02 | 2009-02-04 | Elan Pharma International Limited | Multiparticulate modified release composition |
EP1005863A1 (en) * | 1998-12-04 | 2000-06-07 | Synthelabo | Controlled-release dosage forms comprising a short acting hypnotic or a salt thereof |
PE20001396A1 (en) * | 1999-01-18 | 2000-12-23 | Gruenenthal Chemie | DELAYED MEDICINAL FORMULATIONS CONTAINING A COMBINATION OF AN OPIOID OR A PHYSIOLOGICALLY TOLERABLE SALT OF THE SAME, AN O-AGONIST |
US20030118641A1 (en) * | 2000-07-27 | 2003-06-26 | Roxane Laboratories, Inc. | Abuse-resistant sustained-release opioid formulation |
WO2001008661A2 (en) * | 1999-07-29 | 2001-02-08 | Roxane Laboratories, Inc. | Opioid sustained-released formulation |
KR100345214B1 (en) * | 1999-08-17 | 2002-07-25 | 이강춘 | The nasal transmucosal delivery of peptides conjugated with biocompatible polymers |
ATE280579T1 (en) * | 1999-08-27 | 2004-11-15 | Southern Res Inst | INJECTABLE BUPRENORPHINE MICROSPHERES COMPOSITIONS AND USE THEREOF FOR REDUCING HEROIN AND ALCOHOL CONSUMPTION |
NZ511900A (en) * | 1999-09-30 | 2003-06-30 | Penwest Pharmaceuticals Co | Sustained release matrix systems for highly soluble drugs |
DE60115840T2 (en) * | 2000-01-19 | 2006-07-13 | Mannkind Corp., Danbury | FORMULATION WITH MULTIPLE PULSED ACTIVE COMPOSITION |
PT2092936E (en) * | 2000-02-08 | 2013-06-20 | Euro Celtique Sa | Tamper-resistant oral opioid agonist formulations |
US6716449B2 (en) * | 2000-02-08 | 2004-04-06 | Euro-Celtique S.A. | Controlled-release compositions containing opioid agonist and antagonist |
AU2001275095A1 (en) * | 2000-07-17 | 2002-01-30 | Opt-E-Scrip, Inc. | Single-patient drug trials used with accumulated database |
JP2004505730A (en) * | 2000-08-15 | 2004-02-26 | ユニバーシティ オブ ケンタッキー リサーチ ファウンデーション | Programmable multi-dose intranasal drug delivery device |
CN1592609A (en) * | 2001-05-11 | 2005-03-09 | 恩德制药公司 | Abuse-resistant opioid dosage form |
CA2446550C (en) * | 2001-05-11 | 2012-03-06 | Endo Pharmaceuticals, Inc. | Abuse-resistant controlled-release opioid dosage form |
US20030064122A1 (en) * | 2001-05-23 | 2003-04-03 | Endo Pharmaceuticals, Inc. | Abuse resistant pharmaceutical composition containing capsaicin |
US8329216B2 (en) * | 2001-07-06 | 2012-12-11 | Endo Pharmaceuticals Inc. | Oxymorphone controlled release formulations |
PL207748B1 (en) * | 2001-07-06 | 2011-01-31 | Penwest Pharmaceuticals Company | Sustained release formulations of oxymorphone |
WO2003004032A1 (en) * | 2001-07-06 | 2003-01-16 | Endo Pharmaceuticals, Inc. | Oral administration of 6-hydroxy-oxymorphone for use as an analgesic |
DE60230632D1 (en) * | 2001-07-18 | 2009-02-12 | Euro Celtique Sa | PHARMACEUTICAL COMBINATIONS OF OXYCODONE AND NALOXONE |
US20030044458A1 (en) * | 2001-08-06 | 2003-03-06 | Curtis Wright | Oral dosage form comprising a therapeutic agent and an adverse-effect agent |
US7144587B2 (en) * | 2001-08-06 | 2006-12-05 | Euro-Celtique S.A. | Pharmaceutical formulation containing opioid agonist, opioid antagonist and bittering agent |
US7157103B2 (en) * | 2001-08-06 | 2007-01-02 | Euro-Celtique S.A. | Pharmaceutical formulation containing irritant |
US20030068375A1 (en) * | 2001-08-06 | 2003-04-10 | Curtis Wright | Pharmaceutical formulation containing gelling agent |
WO2003013433A2 (en) * | 2001-08-06 | 2003-02-20 | Euro-Celtique S.A. | Sequestered antagonist formulations |
US7842307B2 (en) * | 2001-08-06 | 2010-11-30 | Purdue Pharma L.P. | Pharmaceutical formulation containing opioid agonist, opioid antagonist and gelling agent |
DE60232417D1 (en) * | 2001-08-06 | 2009-07-02 | Euro Celtique Sa | OPIOID AGONIST FORMULATIONS WITH FREEZER AND SEQUESTRATED ANTAGONIST |
US7141250B2 (en) * | 2001-08-06 | 2006-11-28 | Euro-Celtique S.A. | Pharmaceutical formulation containing bittering agent |
US7332182B2 (en) * | 2001-08-06 | 2008-02-19 | Purdue Pharma L.P. | Pharmaceutical formulation containing opioid agonist, opioid antagonist and irritant |
DE20220910U1 (en) * | 2001-08-06 | 2004-08-05 | Euro-Celtique S.A. | Anti-abuse compositions for opioids |
US20030049272A1 (en) * | 2001-08-30 | 2003-03-13 | Yatindra Joshi | Pharmaceutical composition which produces irritation |
US20030068276A1 (en) * | 2001-09-17 | 2003-04-10 | Lyn Hughes | Dosage forms |
US20030059397A1 (en) * | 2001-09-17 | 2003-03-27 | Lyn Hughes | Dosage forms |
JP2005523876A (en) * | 2001-09-26 | 2005-08-11 | ペンウェスト ファーマシューティカルズ カンパニー | Opioid formulations with reduced potential for abuse |
EP1450824A4 (en) * | 2001-11-02 | 2005-09-28 | Elan Corp Plc | Pharmaceutical composition |
US20030158264A1 (en) * | 2002-02-20 | 2003-08-21 | Ramachandran Radhakrishnan | Orally administrable pharmaceutical formulation comprising ephedrine hydrochloride and process for preparing the same |
US7524515B2 (en) * | 2003-01-10 | 2009-04-28 | Mutual Pharmaceuticals, Inc. | Pharmaceutical safety dosage forms |
JP2008520744A (en) * | 2004-11-19 | 2008-06-19 | ザ・レジェンツ・オブ・ザ・ユニバーシティ・オブ・カリフォルニア | Anti-inflammatory pyrazolopyrimidine |
-
2002
- 2002-09-25 JP JP2003530373A patent/JP2005523876A/en active Pending
- 2002-09-25 CA CA002459976A patent/CA2459976A1/en not_active Abandoned
- 2002-09-25 US US10/254,207 patent/US20030091635A1/en not_active Abandoned
- 2002-09-25 WO PCT/US2002/030393 patent/WO2003026743A2/en active Application Filing
- 2002-09-25 AU AU2002337686A patent/AU2002337686B2/en not_active Ceased
- 2002-09-25 EP EP02773571A patent/EP1429730A4/en not_active Withdrawn
-
2007
- 2007-02-09 US US11/704,848 patent/US20070140975A1/en not_active Abandoned
-
2010
- 2010-04-12 JP JP2010091222A patent/JP2010195807A/en active Pending
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6245357B1 (en) * | 1998-03-06 | 2001-06-12 | Alza Corporation | Extended release dosage form |
Non-Patent Citations (1)
Title |
---|
See also references of EP1429730A4 * |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9492443B2 (en) | 2003-11-26 | 2016-11-15 | Acura Pharmaceuticals, Inc. | Abuse deterrent compositions and methods of making same |
US8901113B2 (en) | 2009-09-30 | 2014-12-02 | Acura Pharmaceuticals, Inc. | Methods and compositions for deterring abuse |
US9572779B2 (en) | 2010-12-22 | 2017-02-21 | Purdue Pharma L.P. | Encased tamper resistant controlled release dosage forms |
US9101636B2 (en) | 2012-11-30 | 2015-08-11 | Acura Pharmaceuticals, Inc. | Methods and compositions for self-regulated release of active pharmaceutical ingredient |
US9320796B2 (en) | 2012-11-30 | 2016-04-26 | Acura Pharmaceuticals, Inc. | Methods and compositions for self-regulated release of active pharmaceutical ingredient |
Also Published As
Publication number | Publication date |
---|---|
US20030091635A1 (en) | 2003-05-15 |
AU2002337686B2 (en) | 2008-05-15 |
JP2005523876A (en) | 2005-08-11 |
JP2010195807A (en) | 2010-09-09 |
EP1429730A4 (en) | 2010-06-16 |
CA2459976A1 (en) | 2003-04-03 |
WO2003026743A2 (en) | 2003-04-03 |
US20070140975A1 (en) | 2007-06-21 |
EP1429730A2 (en) | 2004-06-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2003026743A3 (en) | Opioid formulations having reduced potential for abuse | |
ZA200202640B (en) | Advertisement distribution system and server. | |
AU2001255467A1 (en) | Security systems for delivering goods and services | |
AU2002244133A1 (en) | Delivery systems for mycotechnologies, mycofiltration and mycoremediation | |
WO2005045689A3 (en) | Methods and systems for network coordination | |
AU7477200A (en) | System for selecting, distributing, and selling fonts | |
AU2002244142A1 (en) | Integrated medication delivery system | |
AU2002356545A1 (en) | Internally targeted advertisements using television delivery systems | |
AU2002345577A1 (en) | Protected content distribution system | |
MX261045B (en) | Benefit agent delivery systems. | |
MXPA03007214A (en) | Modulated release particles for aerosol delivery. | |
IL155272A0 (en) | Systems for optimized drug delivery | |
AU2002330886A1 (en) | Novel targeted delivery system for bioactive agents | |
MXPA03002874A (en) | Pesticide delivery system. | |
GB0125018D0 (en) | Service data delivery system | |
AU2002325034A1 (en) | Stent delivery system | |
AU2001282494A1 (en) | System for protection from falls | |
MXPA03007257A (en) | Modulated release particles for aerosol delivery. | |
HK1068502A1 (en) | Passive immunisation against bacillus anthracis. | |
EP1414183A4 (en) | Encrypted data delivery system | |
AU2002343555A1 (en) | Eutectic-based self-nanoemulsified drug delivery system | |
AU2001287089A1 (en) | Systems and methods for providing item sales and delivery service | |
AU2002311856A1 (en) | Pricing delivery system | |
MXPA03007253A (en) | Modulated release particles for aerosol delivery. | |
AU2001260244A1 (en) | Product delivery system |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BY BZ CA CH CN CO CR CU CZ DE DM DZ EC EE ES FI GB GD GE GH HR HU ID IL IN IS JP KE KG KP KR LC LK LR LS LT LU LV MA MD MG MN MW MX MZ NO NZ OM PH PL PT RU SD SE SG SI SK SL TJ TM TN TR TZ UA UG UZ VN YU ZA ZM |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): GH GM KE LS MW MZ SD SL SZ UG ZM ZW AM AZ BY KG KZ RU TJ TM AT BE BG CH CY CZ DK EE ES FI FR GB GR IE IT LU MC PT SE SK TR BF BJ CF CG CI GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2002337686 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2459976 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2003530373 Country of ref document: JP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2002773571 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 2002773571 Country of ref document: EP |